Together, they focus on a shared goal:

Creating a world without cancer.


Funding Opportunities:
External Funding Opportunities

National Institutes of Health / National Cancer Institute



Funding Opportunity


NIH Funding Opportunities


NIH U.S.-China Program for Biomedical Collaborative Research (R01)

February 21, 2019

NIH Alzheimer's-focused administrative supplements for NIH grants that are not focused on Alzheimer's disease

February 26, 2019

NIH Mechanisms of Disparities in Etiology and Outcomes of Lung Cancer in the U.S.: The Role of Risk and Protective Factors  This initiative will support exploratory and developmental multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations.

R01  Deadline:  March 4

R21  Deadline:  March 4


March 4, 2019

NIH Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21)

March 7, 2019

NIH Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21)   

March 7, 2019

NIH Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)

March 7, 2019

NIH Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)

March 7, 2019

NIH Biology of Bladder Cancer  This FOA encourages applications investigating the biology and underlying mechanisms of bladder cancer. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.

  • R01  Deadline:  June 5
  • R21  Deadline:  June 16



NIH Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01)

August 1, 2019

NIH Notice of Intent to Publish a FOA for Diversity Program Consortium Dissemination and Translation Awards (U01)

July 1, 2020

NIH Administrative Supplements to Existing NIH Grants and Cooperative Agreements.  The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. 


Varies by awarding IC






Funding Opportunity


Camille and Henry Dreyfus Foundation’s 2019 Dreyfus Prize in the Chemical Sciences  The Dreyfus Prize, awarded biennially, recognizes an individual for exceptional and original research in a selected area of chemistry that has advanced the field in a major way. The prize consists of a monetary award of $250,000, a medal, and a certificate.  This year’s theme is Chemistry in Support of Human Health.  Any person may nominate a candidate for the Dreyfus Prize. Self-nominations are not accepted. 


February 28, 2019

NSF Biophotonics 

On-going through August 15, 2019

NSF Division of Molecular and Cellular Biosciences: Investigator-initiated research projects (MCB)  



DOE-JGI CSP New Investigator 


NSF Big Ideas updates


DOD-CDMRP Peer Reviewed Medical Research Program  The program includes several mechanisms including:  Discovery Award; Focused Program Award; Investigator-Initiated Research Award, and Technology/Therapeutic Development Award. 


DOD-CDMRP Breast Cancer


The AACR is currently accepting applications for the following opportunities:

Grants for mentored researchers in the areas of lung, ovarian, pediatric, and breast cancer research, lymphoma, myeloma, and all areas of clinical and translational cancer research

A grant for tenure-eligible junior faculty focused on any area of cancer research

A grant for established investigators in the field of neuroendocrine tumor research

Learn More

Apply Now


Limited Submissions

Purdue Internal Deadlines for Proposals

Numerous new opportunities, follow link for details


The Fiscal Year 2019 (FY19) Defense Appropriation Act provides funding for the peer reviewed programs managed by the Department of Defense (DOD) office of Congressionally Directed Medical Research Programs (CDMRP). This e-mail is to notify the research community of recently released pre-announcements ( to allow investigators time to plan and develop ideas for submission to the anticipated FY19 funding opportunities.  


FY19 funding opportunities are anticipated to be released in January 2019 for the following programs:


Breast Cancer Research Program

Ovarian Cancer Research Program


Descriptions of each of the anticipated funding opportunities, eligibility, key mechanism elements, and funding can be found in the respective Program pre-announcement.  FY19 pre-announcements can be found in the CDMRP home page features at



Peer Reviewed Medical Research Program

Clinical Trial Award

Discovery Award

Focused Program Award

Investigator-Initiated Research Award

Technology/Therapeutic Development Award


Detailed descriptions of the funding opportunity, evaluation criteria, and submission requirements can be found in the Program Announcements. The Program Announcements are available electronically for downloading from the website (, the CDMRP website ( and the electronic Biomedical Research Application Portal (eBRAP) (


All CDMRP funding opportunities, both recently and previously released, are available on the CDMRP website (


Subsequent notifications will be sent when additional funding opportunities are released. A listing of all open CDMRP funding opportunities can be obtained on the website by performing a basic search using CFDA Number 12.420.


Submission is a two-step process requiring both pre-application submission and full application submission.  All pre-applications must be submitted through eBRAP (  Full applications from extramural organizations (non-DoD organizations) must be submitted through (  Intramural DoD organizations may submit full applications to either eBRAP or  Refer to the General Application Instructions, Section II.A. for registration and submission requirements for eBRAP and  For detailed information on the submission process, refer to Section II.D. of the Program Announcement/Funding Opportunity.


eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance.  A key feature of eBRAP is the ability of an organization’s representatives and PIs to view and modify the application submissions associated with them.  eBRAP will validate application files against the specific Program Announcement/Funding Opportunity requirements and discrepancies will be noted in an email to the PI and in the Full Application Files tab in eBRAP.  It is the applicant’s responsibility to review all application components for accuracy as well as ensure proper ordering as specified in this Program Announcement/Funding Opportunity. 







  • Purdue University Center for Cancer Research
    Hansen Life Sciences Research Building
    201 S. University Street
    West Lafayette, IN 47907-2064

  • Phone: (765) 494-9129
    Fax: (765) 494-9193
    Contact us with questions at:

© Copyright 2014 The Purdue University Center for Cancer Research is the first NCI funded Center in Indiana.